S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This Stock Could Go Up 66% or More. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:BBI

Brickell Biotech (BBI) Stock Forecast, Price & News

$0.98
+0.04 (+4.26%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.90
$1.00
50-Day Range
$0.58
$0.98
52-Week Range
$2.21
$37.35
Volume
621,334 shs
Average Volume
206,730 shs
Market Capitalization
$2.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BBI stock logo

About Brickell Biotech (NASDAQ:BBI) Stock

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

BBI Price History

BBI Stock News Headlines

Seattle Biotech News
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Nuclear Receptor ROR-Gamma Market Size by 2030
Brickell City Centre
Biotech News
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Best Biotech Penny Stocks
Brickell Biotech
See More Headlines
Receive BBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brickell Biotech and its competitors with MarketBeat's FREE daily newsletter.

BBI Company Calendar

Last Earnings
8/11/2022
Today
9/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BBI
Employees
16
Year Founded
2009

Profitability

Net Income
$-39,470,000.00
Net Margins
-643.48%
Pretax Margin
-643.48%

Debt

Sales & Book Value

Annual Sales
$4.64 million
Book Value
$9.75 per share

Miscellaneous

Free Float
2,744,000
Market Cap
$2.82 million
Optionable
Not Optionable
Beta
0.02

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Reginald L. Hardy M.B.A.Mr. Reginald L. Hardy M.B.A. (Age 64)
    R.Ph., Co-Founder & Chairman
    Comp: $76.83k
  • Attorney Robert Busard Brown (Age 60)
    CEO & Director
    Comp: $816.73k
  • Mr. Andrew D. SklawerMr. Andrew D. Sklawer (Age 38)
    Co-Founder, Pres, COO & Sec.
    Comp: $559.58k
  • Mr. Deepak Chadha M.B.A.Mr. Deepak Chadha M.B.A. (Age 52)
    M.S., MBA, MS, RAC, Chief R&D Officer
    Comp: $543.59k
  • Mr. Albert Nicholas Marchio II (Age 70)
    CFO and Principal Accounting & Financial Officer
  • Mr. David R. Mcavoy J.D.Mr. David R. Mcavoy J.D. (Age 59)
    Gen. Counsel & Chief Compliance Officer
  • Mr. Gary S. Walker (Age 62)
    Chief Marketing Officer
  • Aron Aizenstat M.B.A.
    P.M.P., VP of Corp. Devel. & Operations
  • Ms. Sue Fattor
    Head of Human Resource
  • Ms. Nancy Seretta
    VP & Head of Clinical Operations













BBI Stock - Frequently Asked Questions

How have BBI shares performed in 2023?

Brickell Biotech's stock was trading at $1.50 on January 1st, 2023. Since then, BBI stock has decreased by 34.7% and is now trading at $0.98.
View the best growth stocks for 2023 here
.

How were Brickell Biotech's earnings last quarter?

Brickell Biotech, Inc. (NASDAQ:BBI) released its quarterly earnings results on Thursday, August, 11th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($1.48) by $1.47. Brickell Biotech had a negative net margin of 643.48% and a negative trailing twelve-month return on equity of 156.10%. During the same period in the previous year, the business earned ($7.21) earnings per share.

When did Brickell Biotech's stock split?

Brickell Biotech shares reverse split on the morning of Tuesday, July 5th 2022. The 1-45 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Brickell Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brickell Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (vbiv), Jaguar Health (JAGX), Miragen Therapeutics (MGEN), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Amarin (AMRN), Fortress Biotech (FBIO) and iBio (IBIO).

What is Brickell Biotech's stock symbol?

Brickell Biotech trades on the NASDAQ under the ticker symbol "BBI."

How do I buy shares of Brickell Biotech?

Shares of BBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brickell Biotech's stock price today?

One share of BBI stock can currently be purchased for approximately $0.98.

How much money does Brickell Biotech make?

Brickell Biotech (NASDAQ:BBI) has a market capitalization of $2.82 million and generates $4.64 million in revenue each year. The company earns $-39,470,000.00 in net income (profit) each year or ($13.52) on an earnings per share basis.

How can I contact Brickell Biotech?

Brickell Biotech's mailing address is 5777 CENTRAL AVENUE SUITE 102, BOULDER CO, 80301. The official website for the company is www.brickellbio.com. The company can be reached via phone at (720) 505-4755, via email at ir@brickellbio.com, or via fax at 858-646-1150.

This page (NASDAQ:BBI) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -